Gain Therapeutics Inc [GANX] stock is trading at $1.76, up 10.00%. An important factor to consider is whether the stock is rising or falling in short-term value. The GANX shares have gain 12.10% over the last week, with a monthly amount glided 1.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gain Therapeutics Inc [NASDAQ: GANX] stock has seen the most recent analyst activity on December 06, 2024, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $7. On April 12, 2021, Oppenheimer initiated with a Outperform rating and assigned a price target of $30 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $30 on April 12, 2021.
Gain Therapeutics Inc [GANX] stock has fluctuated between $0.89 and $5.33 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Gain Therapeutics Inc [NASDAQ: GANX] shares were valued at $1.76 at the most recent close of the market. An investor can expect a potential return of 297.73% based on the average GANX price forecast.
Analyzing the GANX fundamentals
Gross Profit Margin for this corporation currently stands at 0.0% with Operating Profit Margin at -330.66%, Pretax Profit Margin comes in at -329.02%, and Net Profit Margin reading is -329.74%. To continue investigating profitability, this company’s Return on Assets is posted at -1.49, Equity is -2.04 and Total Capital is -2.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5800 points at the first support level, and at 1.4000 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9100, and for the 2nd resistance point, it is at 2.0600.
Ratios To Look Out For
For context, Gain Therapeutics Inc’s Current Ratio is 2.99. On the other hand, the Quick Ratio is 2.99, and the Cash Ratio is 2.62.
Transactions by insiders
Recent insider trading involved Mack Gene, CFO and Interim CEO, that happened on Aug 09 ’24 when 14400.0 shares were purchased. Executive Chairman, Islam Khalid completed a deal on Aug 09 ’24 to buy 50000.0 shares. Meanwhile, Director RICHMAN ERIC I bought 17000.0 shares on Jul 01 ’24.
